Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia / Stahl M.; DeVeaux M.; Montesinos P.; Itzykson R.; Ritchie E.K.; Sekeres M.A.; Barnard J.; Podoltsev N.A.; Brunner A.; Komrokji R.S.; Bhatt V.R.; Al-Kali A.; Cluzeau T.; Santini V.; Roboz G.J.; Fenaux P.; Litzow M.; Fathi A.T.; Perreault S.; Kim T.K.; Prebet T.; Vey N.; Verma V.; Germing U.; Bergua J.; Serrano J.; Gore S.D.; Zeidan A.M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 60:(2019), pp. 246-249. [10.1080/10428194.2018.1468893]
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Santini V.;
2019
Abstract
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
| File | Dimensione | Formato | |
|---|---|---|---|
|
stahl2018_MRC e LRF.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.13 MB
Formato
Adobe PDF
|
1.13 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
